Astrana Health (ASTH) vs FTI Consulting (FCN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Astrana Health (ASTH) has outperformed FTI Consulting (FCN) over the past year, gaining 23.4% versus a loss of 15.2%. Over five years, FCN leads with a -5.2% price change compared with -47.5% for ASTH. FTI Consulting is the larger company by market cap ($3.76 billion vs $1.86 billion), about 2.0 times the size, while Astrana Health is growing revenue faster (+56.4% vs +2.4%).
On valuation, Astrana Health trades at a lower forward P/E (10.3x vs 12.5x for FTI Consulting). FTI Consulting converts more of its revenue into profit, with a net margin of 7.1% versus 0.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | FCN |
|---|---|---|
| Share price | $37.55 | $136.16 |
| Market cap | $1.86B | $3.76B |
| 1-day change | +4.68% | -3.09% |
| YTD return | +51.35% | -20.30% |
| 1-year return | +23.44% | -15.20% |
| 5-year return | -47.48% | -5.23% |
| P/E ratio (TTM) | 45.24 | 16.40 |
| Forward P/E | 10.33 | 12.53 |
| EPS (TTM) | $0.83 | $8.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.18B | $3.79B |
| Revenue growth (YoY) | +56.39% | +2.44% |
| Net income (latest FY) | $22.49M | $270.87M |
| Gross margin | 10.73% | 32.13% |
| Operating margin | 2.47% | 10.27% |
| Net margin | 0.71% | 7.15% |
| 52-week high | $51.60 | $189.30 |
| 52-week low | $18.08 | $129.12 |
| Distance from 52-week high | -27.23% | -28.07% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +37.60% | +21.55% |
| Average volume | 458.06K | 428.05K |
| Shares outstanding | 49.60M | 27.61M |
| Employees | 3,000 | 8,124 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Professional Services | Professional Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTI Consulting is about 2.0 times larger than Astrana Health by market value ($3.76B vs $1.86B).
- ASTH has outperformed FCN by 38.6 percentage points over the past year.
- Astrana Health trades at a higher earnings multiple (45.2x vs 16.4x trailing P/E).
- FTI Consulting is more profitable, keeping 7.1 cents of every revenue dollar as net income versus 0.7 cents for Astrana Health.
- Astrana Health grew revenue faster in its latest fiscal year (+56.39% vs +2.44%).
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About FTI Consulting
FCN stock →FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide.
Consumer Discretionary · Professional Services · 8,124 employees
ASTH vs FCN FAQ
Which is bigger, Astrana Health or FTI Consulting?
FTI Consulting (FCN) is larger, with a market capitalization of $3.76B compared with $1.86B for Astrana Health (ASTH).
Which stock has performed better over the past year, ASTH or FCN?
ASTH returned +23.44% over the past 12 months, compared with -15.20% for FCN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASTH or FCN?
FCN has the lower trailing P/E at 16.4, versus 45.2 for ASTH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Astrana Health and FTI Consulting in the same industry?
Yes. Both are classified in the Professional Services industry within the Consumer Discretionary sector.